Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Endometrioid Adenocarcinoma

Explore clinical trials studying Fallopian Tube Endometrioid Adenocarcinoma. Study availability and eligibility vary by location and protocol.

22 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Endometrioid Adenocarcinoma trial results

Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 695 locations
View Trial Details
Recruiting

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

NCT06639074

Conditions
Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, +15 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Active, not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT02345265

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 20 locations
View Trial Details
Active, not recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03587311

Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
View all 23 locations
View Trial Details
Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 398 locations
View Trial Details
Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01167712

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +50 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 564 locations
View Trial Details

Related conditions